Clinical Trial Detail

NCT ID NCT02932280
Title Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

central nervous system cancer

lymphoma

Advanced Solid Tumor

leukemia

Therapies

Neratinib

Age Groups: adult child

No variant requirements are available.